Literature DB >> 9042166

Marijuana to prevent nausea and vomiting in cancer patients: a survey of clinical oncologists.

R H Schwartz1, E A Voth, M J Sheridan.   

Abstract

Marijuana, if rescheduled by the Drug Enforcement Agency, would be the only Food and Drug Administration (FDA)-approved drug to be administered by smoking. American physicians need timely, factual information about probable usage patterns and potential adverse effects of medical marijuana, and a factual complete review of the literature on the subject. We mailed a survey to 1,500 American clinical oncologists. Of particular interest was whether and how often in the past 24 months these physicians recommended smoked marijuana, synthetic tetrahydrocannabinol, or 5-HT3 (serotonin) antagonists (ondansetron [Zofran], granisetron [Kytril]) for their patients. We also inquired whether and how often the oncologists would prescribe marijuana in the form of cigarettes, were it to be FDA-approved. Completed surveys were received from 1,122 (75%) of the oncologists. The percentages of oncologists who prescribed or recommended selected antiemetics more than five times between 1992 and 1994 were 98% for 5-HT, antagonists, 6% for dronabinol (Marinol), and 1% for smoked marijuana. We also found that 332 (30%) of the oncologist-respondents to this nationwide survey supported rescheduling of marijuana for medical purposes; however, two thirds (67%) of the 332 respondents who were in favor of rescheduling estimated that they would write less than one prescription per month for marijuana cigarettes. A comprehensive literature review failed to provide persuasive evidence to recommend marijuana as a needed antiemetic medicine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042166     DOI: 10.1097/00007611-199702000-00001

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  13 in total

1.  Should physicians support the medical use of marijuana? No: evidence of its safety and efficacy is weak. Counterpoint.

Authors:  Eric A Voth
Journal:  West J Med       Date:  2002-03

2.  Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Authors:  Catherine Lombard; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

3.  Pharmacy Student Knowledge, Confidence and Attitudes Toward Medical Cannabis and Curricular Coverage.

Authors:  Frank J Caligiuri; Erin E Ulrich; Kelli Jo Welter
Journal:  Am J Pharm Educ       Date:  2018-06       Impact factor: 2.047

4.  Pharmacy Students' Knowledge and Attitudes Regarding Medical Marijuana.

Authors:  Karen E Moeller; Barbara Woods
Journal:  Am J Pharm Educ       Date:  2015-08-25       Impact factor: 2.047

5.  Exploratory Factor Analysis of Medical Students' Perceptions of Medical Cannabis Scale.

Authors:  Robin J Jacobs; Michael N Kane
Journal:  Cureus       Date:  2022-06-08

Review 6.  Medical marijuana.

Authors:  J B Marmor
Journal:  West J Med       Date:  1998-06

7.  Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study.

Authors:  Ilana M Braun; Alexi Wright; John Peteet; Fremonta L Meyer; David P Yuppa; Dragana Bolcic-Jankovic; Jessica LeBlanc; Yuchiao Chang; Liyang Yu; Manan M Nayak; James A Tulsky; Joji Suzuki; Lida Nabati; Eric G Campbell
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

8.  Cannabis in medicine: a national educational needs assessment among Canadian physicians.

Authors:  Daniel Ziemianski; Rielle Capler; Rory Tekanoff; Anaïs Lacasse; Francesca Luconi; Mark A Ware
Journal:  BMC Med Educ       Date:  2015-03-19       Impact factor: 2.463

9.  Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey.

Authors:  Des Crowley; Claire Collins; Ide Delargy; Eamon Laird; Marie Claire Van Hout
Journal:  Harm Reduct J       Date:  2017-01-13

Review 10.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.